Plain-English translation of NCT04763356 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new way to help cancer patients manage chemotherapy-induced peripheral neuropathy—nerve damage in the hands and feet caused by cancer medications like taxanes, platinum drugs, and certain targeted therapies. The study compares two approaches: standard care where you manage symptoms on your own, versus a new model where you report symptoms daily and a nurse practitioner calls you back to help adjust your treatment if symptoms worsen.
Nerve damage from cancer drugs is common and painful, but it's often managed reactively—only when patients reach out to their doctors. This trial exists to see whether proactive daily monitoring and quick responses from a trained nurse can prevent symptoms from getting worse and improve quality of life.
You likely qualify if…
You likely don't qualify if…
You will report your nerve damage symptoms every day using a smartphone app, website, or automated phone system for 12 weeks. You'll come in for study visits at the start, at 6 weeks, and at 12 weeks. Depending on which group you're assigned to, either your usual cancer care team will manage your symptoms as they normally do, or a nurse practitioner will call you back whenever your symptoms spike to help adjust your medications or treatments based on evidence-based guidelines.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States